Seres Stops Enrollment In Melanoma Study, Deprioritizes Further Development

  • Seres Therapeutics Inc (NASDAQ: MCRB) and its study partners have voluntarily discontinued further enrollment in the Phase 1 study evaluating SER-401 in metastatic melanoma.
  • The company cited challenges related to the pandemic.
  • The study was assessing the safety and drug activity of SER-401 or fecal microbiota transplant (FMT) in combination with nivolumab.
  • A preliminary analysis of results from 10 subjects indicated that SER-401 was safe and well-tolerated.
  • No patients were enrolled in the FMT portion of the study.
  • Subjects currently enrolled in the study will complete the study protocol. 
  • Price Action: MCRB shares gained 0.73% at $19.2 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralmelanomaphase 1
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!